Skip to content

Research at St Andrews

Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy

Research output: Contribution to journalArticle


Andris Zeltins, Jonathan West, Franziska Zabel, Aadil El Turabi, Ina Balke, Stefanie Haas, Melanie Maudrich, Federico Storni, Paul Engeroff, Gary T Jennings, Abhay Kotecha, David I Stuart, John Foerster, Martin F Bachmann

School/Research organisations


Monoclonal antibodies are widely used to treat non-infectious conditions but are costly. Vaccines could offer a cost-effective alternative but have been limited by sub-optimal T-cell stimulation and/or weak vaccine responses in recipients, for example, in elderly patients. We have previously shown that the repetitive structure of virus-like-particles (VLPs) can effectively bypass self-tolerance in therapeutic vaccines. Their efficacy could be increased even further by the incorporation of an epitope stimulating T cell help. However, the self-assembly and stability of VLPs from envelope monomer proteins is sensitive to geometry, rendering the incorporation of foreign epitopes difficult. We here show that it is possible to engineer VLPs derived from a non human-pathogenic plant virus to incorporate a powerful T-cell-stimulatory epitope derived from Tetanus toxoid. These VLPs (termed CMVTT) retain self-assembly as well as long-term stability. Since Th cell memory to Tetanus is near universal in humans, CMVTT-based vaccines can deliver robust antibody-responses even under limiting conditions. By way of proof of concept, we tested a range of such vaccines against chronic inflammatory conditions (model: psoriasis, antigen: interleukin-17), neurodegenerative (Alzheimer's, β-amyloid), and allergic disease (cat allergy, Fel-d1), respectively. Vaccine responses were uniformly strong, selective, efficient in vivo, observed even in old mice, and employing low vaccine doses. In addition, randomly ascertained human blood cells were reactive to CMVTT-VLPs, confirming recognition of the incorporated Tetanus epitope. The CMVTT-VLP platform is adaptable to almost any antigen and its features and performance are ideally suited for the design of vaccines delivering enhanced responsiveness in aging populations.


Original languageEnglish
Article number30
Number of pages13
Journalnpj Vaccines
Publication statusPublished - 23 Oct 2017

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Narrowband ultraviolet B treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments

    Boswell, K., Cameron, H., West, J., Fleming, C., Ibbotson, S., Dawe, R. & Foerster, J., Nov 2018, In : British Journal of Dermatology. 179, 5, p. 1148-1156 9 p.

    Research output: Contribution to journalArticle

  2. Narrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practice

    Foerster, J., Boswell, K., West, J., Cameron, H., Fleming, C., Ibbotson, S. & Dawe, R., 3 Aug 2017, In : PLoS ONE. 12, 8, 14 p., e0181813.

    Research output: Contribution to journalArticle

  3. HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

    West, J., Ogston, S., Berg, J., Palmer, C., Fleming, C., Kumar, V. & Foerster, J., Aug 2017, In : Clinical and Experimental Dermatology. 42, 6, p. 651-655 5 p.

    Research output: Contribution to journalArticle

  4. Methotrexate in psoriasis under real-world conditions: long-term efficacy and tolerability

    West, J., Ogston, S., Palmer, C., Fleming, C., Dawe, R., Kumar, V., Waterston, S. & Foerster, J., Jun 2016, In : British Journal of Dermatology. 174, 6, p. 1407-1410 4 p.

    Research output: Contribution to journalComment/debate

  5. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials

    West, J., Ogston, S. & Foerster, J., 11 May 2016, In : PLoS ONE. 11, 5, 14 p., e0153740.

    Research output: Contribution to journalArticle

ID: 260534123